Linda A. Adreveno
Corporate Officer/Principal bei Society Of Human Resources Management
Profil
Linda A.
Adreveno currently works at Society Of Human Resources Management, as Member.
Ms. Adreveno also formerly worked at Nektar Therapeutics, as Senior Director-Human Resources from 2001 to 2006, MannKind Corp., as Senior Vice President-Human Resources, and Neos Therapeutics, Inc., as Vice President-Human Resources.
Ms. Adreveno received her undergraduate degree from Excelsior College (New York) and graduate degree from John F.
Kennedy University.
Aktive Positionen von Linda A. Adreveno
| Unternehmen | Position | Beginn |
|---|---|---|
| Society Of Human Resources Management | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Linda A. Adreveno
| Unternehmen | Position | Ende |
|---|---|---|
| NEKTAR THERAPEUTICS | Personalreferent | 01.01.2006 |
| NEOS THERAPEUTICS, INC. | Personalreferent | - |
| MANNKIND CORPORATION | Personalreferent | - |
Ausbildung von Linda A. Adreveno
| Excelsior College (New York) | Undergraduate Degree |
| John F. Kennedy University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MANNKIND CORPORATION | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Society Of Human Resources Management | |
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
